Dr. Usmani on Combining Daratumumab for Multiple Myeloma

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses combining daratumumab (Darzalex) for patients with multiple myeloma.

Depending on the therapy that patients have received for their first-line of treatment, daratumumab may have the ability to be paired with other agents, explains Usmani.

A concern that physicians have is long-term effects of daratumumab on the immune system. As of now, there is no clinically significant concerns but it is something we will continue to watch, states Usmani.